跳到页面内容
pepts.wiki

我们不是医生,此处的内容均不构成医疗建议。请务必先咨询医疗专业人员。 我们为何这样表述

机器翻译,以英文为准。 阅读英文原文

Five ways the wiki draws an idea

Dark teal glass on a light page, after the My-Pepts graphics. Every one below is live, drawn from the retatrutide page's own data, and each says in text what it shows.

Type 1

Steps

A short sequence that has a real order: reconstitution, how a trial is run, how a compound reaches a license. Cards arrive along a rail, once.

从粉末到测量好的样品

对任何冻干小瓶都是同样的四个步骤。仅指实验室操作,并非用于人体。

  1. 1. 阅读小瓶标签

    标签给出小瓶中肽的质量,单位为毫克。这个数字是所有计算的起点。

  2. 2. 加入稀释剂

    将量好的稀释剂沿玻璃壁缓慢加入。轻轻旋转;摇晃可能损伤肽。

  3. 3. 计算浓度

    浓度等于质量除以体积:10 毫克溶于 2 毫升即为每毫升 5 毫克。

  4. 4. 量取样品

    体积等于所需质量除以浓度。在 U-100 注射器上,1 毫升即 100 单位。

Type 2

Orbit

One thing and what it acts on: a molecule and its receptors, a blend and its parts. Lines flow outward; picking a node explains it.

一种分子,作用于什么

它结合的靶点,以及每个受体已知的作用。请选择一项。

RetatrutideGIPGLP-1GCG

GIP receptor. In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake 6.

Type 3

Trial bars

Results by arm of a published trial, switched by outcome. Comparators are pink. A hidden table carries the same numbers for screen readers.

试验测量了什么

每个柱子代表已发表试验中的一个组别:分配到该剂量组的人群平均变化。请选择一项结局指标。

Change in body weight at 48 weeks

Change in body weight at 48 weeks
ArmMean change
Placebo (comparator)-2.1%
1 mg-8.7%
4 mg-17.1%
8 mg-22.8%
12 mg-24.2%

Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose.

粉色柱子为对照组。试验结果是受监测人群的平均值,并非对某个人的预测。

Type 4

Timeline ribbon

A compound's history, year by year, lighting in order along a line. Scrolls sideways on a phone.

从首次试验到今天

Retatrutide: 逐年展示。左右滚动可查看完整时间线。

  1. 2019

    The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA 5.

  2. 2021

    The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins 210.

  3. 2022

    The discovery paper and the phase 1b results are published under the code LY3437943 56.

  4. 2023

    The phase 2 results in obesity and in type 2 diabetes are published 12.

  5. 2024

    The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered 3412.

  6. 2025

    A systematic review and meta-analysis pools four placebo-controlled trials 7.

  7. 2026

    The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published 49.

Type 5

Evidence ladder

Where a compound stands between cell studies and a licensed medicine, with what PubMed holds. It is on every compound page, stubs included.

它攀登到了哪一级

每种药物都要攀登同一架阶梯。大多数化合物从未到达顶端,其所处位置决定了其主张能有多大的依据。

  1. 已获许可的药物

    监管机构已审查这些试验,并批准其用于特定用途。

  2. Phase 3: Retatrutide

    大型随机试验,通常有数千人,与安慰剂或标准治疗对照。

  3. Phase 2

    中等规模试验,在患有相应疾病的人群中测量剂量与效果的关系。

  4. Phase 1 and early human studies

    首次在人体中进行的研究:安全性以及身体如何处理该物质。

  5. 细胞与动物

    实验室及动物研究。动物实验的结果不等同于人体结果。

219
PubMed 上的论文
133
其中以人为对象的研究
11
随机试验
136
综述

文献数量只说明发表了多少,并不说明结果如何。在 PubMed 上统计的数量: 2026-11-16

And in three dimensions

The bead chain

Every compound has its own chain, grown from its name: the wiki's picture of a peptide. On a wide screen it turns slowly in 3D and leans toward the pointer; on a phone, with reduced motion or without WebGL it is a still drawing.

Open this page on a wider screen to see it turn.